Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | EDNRA | P25101 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2626467 | 0.89 | ALDH1A1 (0.59) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL14683655 | 0.88 | ALDH1A1 (0.62) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL2626431 | 0.86 | SCN9A (0.52) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL2626477 | 0.86 | KMT2A (0.54) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL2625950 | 0.85 | KMT2A (0.52) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL1576448 | 0.85 | ALDH1A1 (0.58) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL1576265 | 0.83 | CA1 (0.52) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL1576788 | 0.83 | ALDH1A1 (0.59) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL1576879 | 0.83 | KMT2A (0.55) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL2625921 | 0.81 | KMT2A (0.48) | KMT2AMEN1ALDH1A1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586589-B2 | Piperidine and piperazine phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
| US-8309587-B2 | Piperidine and piperazine phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309587-B2 | Piperidine and piperazine phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-7799822-B2 | Phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799822-B2 | Phenyl sulfonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, TRPA1, TRPV5 | KMT2A 1777/4885MEN1 4592/4885ALDH1A1 2795/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | KMT2A 2855/4885MEN1 2498/4885ALDH1A1 1645/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | KMT2A 1452/4885MEN1 4203/4885ALDH1A1 2531/4885 |
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | TRPV1, TRPV5, TRPA1 | KMT2A 1129/4885MEN1 4701/4885ALDH1A1 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.